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Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.02.038Objective: We tested the hypothesis that duration of donor brain injury and death
would have an adverse effect on recipient rejection and mortality in pediatric heart
transplantation.
Methods: Ninety-three cardiac transplants were performed at our center from July 1,
1997, through June 30, 2003. The primary study end points were the number of
rejection episodes and the time to first rejection. Secondary outcomes were early and
late mortality.
Results: Among 88 recipients of 93 cardiac allografts, 5 (6%) and 1 (1%) received
second and third allografts, respectively. Overall patient mortality (3 early and 2
late) was 6% (5/88), and overall graft loss was 6% (6/93). Median time from donor
brain injury to declaration of brain death (brain injury interval), time from brain
death to donor cardiectomy (brain death interval), and graft ischemia time were 38,
24, and 3.3 hours, respectively. Cox regression analysis (adjusting for United
Network for Organ Sharing status, ventilator dependence, extracorporeal membrane
oxygenation and ventricular-assist device status, diagnosis of congenital heart
disease, sex and cytomegalovirus mismatches, and type of immunosuppression)
demonstrated that recipients of donor hearts with relatively long periods from brain
injury to death declaration or from death to organ removal had significantly
improved rejection-free survival (hazard ratios 0.3, P  .01, and 0.5, P  .05, for
brain injury and brain death times, respectively). Prolonged donor heart ischemia
did not impact rejection rate. Increasing brain injury interval, brain death interval,
and graft ischemia time had no significant effect on mortality.
Conclusion: Longer brain injury and death intervals correlated with improved
freedom from rejection but had no effect on mortality.
T he evolution of heart transplantation has witnessed dramatic progress in earlyrejection detection, perioperative management, and targeted immunosup-pressive agents, thereby extending therapeutic benefits to the young and
patients with complex congenital heart disease.1-5 However, despite an important
steady increase in actuarial survival and reduction in early mortality, graft half-life
is only 12 years,5 primarily because of late graft failure from graft vasculopathy.6,7
The causes of early and late allograft dysfunction and ultimate graft loss are
unclear, certainly multifactorial with underlying complex pathogenesis, and her-
alded by immune and nonimmune damage to endothelial cells, resulting in myointi-
mal proliferation and subsequent vasculopathy.8-10 Kidney graft survival rates from
unrelated living donors are comparable to those from haplotype-matched living
related donors and superior to those from randomly matched cadaveric donors,
implicating profound physiologic and structural derangements that occur from brain
death.11,12 This phenomenon is observed in domino heart allografts, whereby hearts
explanted from recipients of heart-lung transplantation provide a unique source of
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to recipient cohorts of cadaveric donors.13
Brain death is heralded by a cascade of hematologic,
autonomic, endocrinologic, metabolic, and nutritional ef-
fects that set the stage for ischemia-reperfusion injury and
apoptosis in the donor organ.10,14-18 Additionally, the im-
munologic and inflammatory effects increase the expression
of major histocompatibility complex antigens, upregulate
cytokines and lymphocytes, and enhance expression of cell
adhesion molecules, ultimately spawning microvascular en-
dothelial changes that potentially indelibly affect the new
life of the allograft in the recipient.19-30
Data relating donor brain injury and death to outcomes
after heart transplantation remain scarce. We tested the
hypothesis that duration of donor brain injury and declara-
tion of death before allograft recovery would have adverse
short- and intermediate-term effects on freedom from rejec-
tion and overall mortality.
Methods
Patients
The pediatric heart transplantation database at our center was
reviewed from July 1, 1997, through June 30, 2003. Charts were
assessed for age, immunosuppression regimen, extracorporeal
membrane oxygenation and ventricular-assist device status, venti-
TABLE 1. Donor allograft and recipient characteristics
Variable
Donor allografts (n  93)
Age (y)
Mean  SD 20.4 14.9
Range 0.9-57.6
Age 18 y (No.) 34 (37%)
Age 36 y (No.) 16 (17%)
Cytomegalovirus mismatch (No.) 47 (51%)
Donor/recipient height ratio (mean  SD) 1.10 0.43
Donor/recipient weight ratio (mean  SD) 1.86 1.87
Female sex (No.) 32 (34%)
Sex mismatch (No.) 16 (17%)
Ischemic time (min)




Mean  SD 9.5 6.2
Range 0-20
Preoperative mechanical assist (No.) 18 (20%)
Congenital heart disease (No.) 33 (37%)
Dilated cardiomyopathy (No.) 42 (48%)
Restrictive cardiomyopathy (No.) 6 (7%)
Transplant coronary artery disease (No.) 6 (7%)
United Network for Organ Sharing status 1 (No.) 59 (67%)
Ventilator dependency (No.) 18 (20%)lator status, United Network for Organ Sharing status, sex mis-
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mismatch, brain injury and death intervals, and allograft ischemia
time. The cause of brain death was divided into five categories:
intracranial bleeding, trauma, gunshot wound, anoxia, and other
(tumor, infection, and drug overdose). The pretransplantation time
was the sum of three intervals: brain injury interval, brain death
interval, and allograft ischemia time. Brain injury interval was the
period between brain injury or donor admission to the hospital and
declaration of brain death. Brain death interval was the period
between death declaration and application of the donor aortic
crossclamp. The donor allograft ischemia time was the interval
between application of the donor aortic crossclamp and aortic
unclamping in the recipient. The primary end points were number
of rejection episodes and time to first rejection. A secondary
outcome was mortality. Mortality was early (in the hospital) after
engraftment or late (out of the hospital). Donor allografts were
preserved with University of Wisconsin solution. Bicaval tech-
nique was used for the systemic venous atrium when feasible, and
reperfusion was carried out with leukocyte-depleted, aspartate- and
glutamate-enriched warm blood cardioplegia and blood. Approval
for this study was obtained from the University of California Los
Angeles institutional review board.
Immunosuppression
In July 1997, tacrolimus began to replace cyclosporine (INN:
ciclosporin) in our triple-drug immunosuppression regimen of a
calcineurin inhibitor, azathioprine, and steroids, particularly for
high-risk patients. High-risk patients included those with a history
of congenital heart disease, elevated preformed reactive antibod-
ies, multiple blood transfusions, and exposure to mechanical cir-
culatory assistance. Mycophenolate mofetil was also substituted
for azathioprine for high-risk patients older than 14 years. Patients
already receiving cyclosporine before July 1997 were switched to
tacrolimus only in the event of rejection. Those children receiving
cyclosporine without episodes of rejection were continued on this
calcineurin inhibitor. After 1999, all new transplant recipients
were begun on tacrolimus-based immunosuppression. Corticoste-
roid dosing was consistent throughout the study period. Prednisone
was tapered off over the 6 to 12 month if clinically appropriate.
Episodes of biopsy-proven rejection (grade IIIA or higher) or
suspected rejection by clinical presentation (history, physical ex-
amination, and echocardiography) were treated with a combination





No. % No Yes* Alive Dead†
Intracranial
bleeding
19 20 5 (26%) 14 (74%) 16 (84%) 3 (16%)
Trauma 36 39 11 (30%) 25 (69%) 34 (94%) 2 (6%)
Gunshot wound 11 12 1 (9%) 10 (91%) 10 (91%) 1 (9%)
Anoxia 19 20 10 (53%) 9 (47%) 19 (100%) 0 (0%)
Other‡ 8 9 3 (38%) 5 (62%) 8 (100%) 0 (0%)
*Per Fisher exact test, P  .16. †Per Fisher exact test, P  .32. ‡Other
causes were brain tumor, infection, and drug overdose.of intravenous pulse methylprednisolone for 3 days, plasmaphere-
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first week after surgery.
Rejection Surveillance and Treatment
Whenever possible, prospective and serial postoperative donor-
specific cytotoxic and flow cytometric crossmatch (recipient serum
with donor spleen and lymph node tissue) were performed in
sensitized children or patients deemed at risk for early rejection. A
lone retrospective crossmatch was performed on all patients re-
gardless of preformed reactive antibody status in the immediate
postoperative period. Surveillance endomyocardial biopsies were
performed weekly during the first month after transplantation and
regularly according to our protocol. Cellular rejection with hemo-
dynamic compromise was treated aggressively with steroid pulse
therapy and anti-CD3 monoclonal antibody. Plasmapheresis, oral
cyclophosphamide, and intravenous immunoglobulin were consid-
ered for suspected humoral rejection. Follow-up biopsies were
performed 2 to 4 weeks after a grade 1B (International Society for
Heart and Lung Transplantation) or greater result from any biopsy. 3
Biopsies were usually performed on patients with symptoms im-
plicating rejection. Important signs and symptoms included new
onset of at least one of the following: respiratory distress, exercise
intolerance, palpitations, arrhythmia, moderate abdominal pain,
Figure 1. Kaplan-Meier plots showing relationship of cause of
donor death and rejection-free survival (time to first rejection).
ICB, Intracranial bleeding; GSW, gunshot wound.
TABLE 2B. Effects of donor cause of death on acute rejec
Cause of donor death No. %
Intracranial bleeding, trauma, and other 63 68
Gunshot wound 11 12
Anoxia 19 20
*Per Fisher exact test, P  .05. †Per Fisher exact test, P  .53.nausea, emesis, or tachycardia, along with a greater than 15%
The Journal of Thoracidecrease in ejection fraction on echocardiography. A single car-
diovascular pathologist at our institution graded the degree of
cellular rejection according to the International Society for Heart
and Lung Transplantation working criteria. Immunohistochemical
testing was performed to confirm the presence of rejection in
specimens with greater than grade 1B rejection. This methodology
included staining for CD3, CD20, and CD68. Rejection was con-
firmed by the presence of few B cells, an abundance of T lym-
phocytes, and more than 50% macrophages. Specimens with ex-
uberant B lymphocytes and sparse macrophages were reclassified
as International Society for Heart and Lung Transplantation Quilty
Figure 2. Kaplan-Meier plots showing relationship of brain injury
interval and rejection-free survival (time to first rejection).
and mortality
Rejection Mortality
No* Yes Alive Dead†
19 (30%) 44 (70%) 58 (92%) 5 (8%)
1 (9%) 10 (91%) 10 (91%) 1 (9%)
10 (53%) 9 (47%) 19 (100%) 0 (0%)
TABLE 3. Effect of donor cause of death on grouped num-
ber of rejection episodes
No. of rejection episodes
Cause of donor death 0 1 2 3-10
Intracranial bleeding,
trauma, and other
19 (30%) 23 (37%) 11 (17%) 10 (16%)
Gunshot wound 1 (9%) 1 (9%) 3 (27%) 6 (6%)
Anoxia 10 (53%) 3 (16%) 1 (5%) 5 (26%)
Per Fisher exact test, P  .01.tionB lesions.
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pirically for rejection events without endomyocardial biopsy and
patients with grade IIIA or higher rejection in biopsy samples were
counted as having rejection episodes.
Statistical Methods
Donor brain injury interval (in days) was grouped into three
categories (0-1, 2-3, and 4 days) to obviate concerns regarding a
nonlinear response. Similarly, brain death duration (in hours) and
donor allograft ischemia time (in minutes) were grouped by quar-
tiles (0-16, 24, 34 and 90 hours, and 58-152, 153-201,
202-276, and 277-500 minutes). Finally, the number of rejection
episodes per donor allograft was divided into four groups (0, 1, 2,
and 3) because of the dearth of recipients with more than three
rejection episodes.
Analysis of dichotomous or noncontinuous variables was per-
formed with the Fisher exact test. Kaplan-Meier survival and Cox
proportional hazard regression analysis were used to determine the
relationship of donor brain injury interval, donor brain death
duration, and allograft ischemia time to the time to first rejection
and mortality (overall, early, and late). Multivariable analysis was
performed, controlling for predictors of poor outcome. All P
values were 2-sided.
Results
Eighty-eight patients received 93 allografts at University of
California Los Angeles from July 1, 1997, through June
2003. Five patients and 1 patient had second and third
allografts, respectively, during the study period. A single
child received two grafts within a 5-day span and ultimately
died of early graft failure from hyperacute rejection. Donor
Figure 3. Kaplan-Meier plots showing relationship of brain death
interval and rejection-free survival (time to first rejection).and recipient variables are listed in Table 1.
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The most common cause of brain death was related to blunt
trauma, in 36 donors (39%). Nineteen donors (20%) sus-
tained intracranial bleeding, and an equal number had brain
anoxia. Eleven of the donors (12%) died of gunshot
wounds, and 8 (9%) sustained other mechanisms, including
primary brain tumor and infection. Univariate analysis dem-
onstrated no important effect of donor cause of death on
rejection episodes and mortality (P  .16 and P  0.32,
respectively; Table 2A). However, gunshot wound and an-
oxic mechanisms of brain death had higher and lower per-
centages of total number of rejections, respectively, than the
aggregate group of intracranial bleeding, trauma, and other
(P  .05; Table 2B and Figure 1). This important associa-
tion persisted when broken down to groups by number of
rejection episodes (0, 1, 2, and 3-10 rejection episodes, P 
.01; Table 3). The cause of brain injury bore no statistically
important relationship to brain injury and death intervals or
allograft ischemia time.
Brain Injury and Death Intervals
Longer brain injury intervals were associated with improved
rejection-free survival (log-rank P  .03; Figure 2). Brain
injury intervals of 2 to 3 days showed a trend toward
improved rejection-free survival relative to an interval
shorter than 1 day (P  .07, hazard ratio 0.58, 95% confi-
dence interval 0.32-1.06), but longer intervals of 4 to 17
days fared better (P  .015, hazard ratio 0.37, 95% confi-
dence interval 0.17-0.82; Figure 2). There was no important
association between brain injury interval and recipient mor-
tality. The allografts with the longest brain death interval
Figure 4. Kaplan-Meier plot showing overall patient survival for
88 unique recipients.(35-90 hours) demonstrated a trend toward improved rejection-
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 .07; Figure 3), but there was no overall trend with
increased brain death time (log-rank P  .31). Graft isch-
emia bore no statistically significant relationship to
rejection-free survival (log-rank P  .72), number of rejec-
tion episodes, or mortality. Multifactorial analysis testing
the relationship between brain injury and brain death inter-
vals on rejection-free survival (adjusting for sex and cyto-
megalovirus mismatch, preoperative extracorporeal mem-
brane oxygenation or ventricular-assist device, United
Network for Organ Sharing status 1, ventilator dependence,
congenital heart disease diagnosis, and cause of donor
death) revealed that death by gunshot wound (P  .008),
tacrolimus instead of cyclosporine (hazard ratio 0.3, P 
.003), longer brain injury interval of 4 to 17 days (P  .01),
and longer brain death interval of 35 to 90 hours (P  .05)
resulted in better outcomes.
Mortality
The mortality was low in this study. There were 3 early
deaths and 2 late deaths in this cohort during the study time
span (Figure 4). Two in the former group died of early graft
and multiorgan failure related to donor issues (eg, older
donor age), and another child died of hyperacute rejection.
The 2 late deaths in the series resulted from acute cellular
rejection 2 and 6 months after engraftment (Table 4).
Discussion
Evidence continues to mount that disturbed macrocircula-
tion and microcirculation, surging neuroendocrine dis-
charge, and inflammatory mediator release associated with
brain death injure the donor allograft well before engraft-
ment in potential heart recipients.14-16,19 Strategies to ame-
liorate this deleterious milieu created by donor brain injury
and death may delay graft vasculopathy and prolong the
rather short half-life of pediatric heart transplants.
Contrary to our expectations, the findings from this study
suggest that longer durations of brain injury and death
intervals before donor organ recovery and engraftment are
associated with better rejection-free survival in pediatric
TABLE 4. Recipient mortality after orthotopic heart transp
Case Diagnosis Age ECMO Donor age
1 DCM 8 Yes 51
2 CHD 14 No 17
3 Rejection 5 No 8
4 CHD 1.7 No 34
5 CHD 15 No 16
DCM, Dilated cardiomyopathy; CHD, congenital heart disease; ECMO, extheart transplantation. The donor pretransplantation time and
The Journal of Thoracimodality of donor death had no effect on mortality outcome.
These findings are consistent with reports in the kidney
transplantation literature9,11,12 but are at odds with a recent
report by Cantin and colleagues23 suggesting that increased
donor pretransplantation time (72 hours) is associated with
poorer outcome, as measured by treated rejection incidence.
On the basis of their findings, Cantin and colleagues23
questioned a policy of delaying harvest operations and
diagnostic procedures on brain-dead patients until donor
facility elective schedules are completed and an operating
room becomes available. Potential explanations for this
difference may lie in inherent biologic differences in re-
sponses of pediatric versus adult recipients to heart allo-
grafts, differing rejection surveillance methods and criteria
for what constitutes a rejection episode, and varied immu-
nosuppression regimens. Indeed, our study may be under-
powered to assess mortality outcomes because of our low
casualties and only short- to medium-term follow-up. Over-
reliance on less defined clinical end points and lack of
specific markers associated with the deleterious effect of
donor brain death on the cardiac allograft obscure heads-up
comparison. Another intriguing explanation for these find-
ings suggest that mediators of endothelial cell injury during
the pretransplantation time manifest dynamic rather than
static kinetics and longer brain injury and death intervals
may permit resuscitation, dissipation and partial resolution
or attenuation.
Animal models (rat heart, kidney and liver) of acute
rejection demonstrate worse rejection-free survival from
allografts of brain-dead donors than living controls. These
grafts exhibited accelerated inflammatory response in the
recipient host marked by rapid mononuclear cell infiltration
and production of cytokines, chemokines and adhesion mol-
ecules (15, 21). Similar phenomena may exist in human
models of solid organ transplantation. Future identification
of these proteins may provide fingerprints or biomarkers for
therapeutic intervention and modulation.
Study Limitations




Yes No Early graft failure, died postoperative d 3
Yes No Hyperacute rejection (retransplantation)
No Yes Severe acute rejection at 8 wk
Yes No Right ventricular failure, extracorporeal
membrane oxygenation, sepsis
No Yes Acute rejection and sepsis
oreal membrane oxygenation.lantatively short follow-up, and small sample size, which may
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inflammatory and immunologic consequences of brain
death are associated with important effects on outcome in
animal and human models of solid organ transplantation.
The effect of duration of this insult on the primary end point
of rejection was contrary to our original expectation. The
effect on the secondary end point of mortality—at least in
the short and intermediate terms—was not met, hence the
null hypothesis remains viable. Confirmation of these find-
ings awaits careful prospective analysis with larger sample
sizes and longer follow-up. The potential to blunt the del-
eterious effect of brain death with therapeutic pretreatment
of donor cadaver organ earlier in the donor organ supply
chain is a fruitful area of research and may increase donor
allograft half-life. This may ultimately require study and
measurement of specific biologic markers of brain death in
the donor, thereby establishing dose-response curves and
newer therapeutic strategies.
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Discussion
Dr Leonard L. Bailey (Loma Linda, Calif ). Pediatric heart trans-
plantation has been around for about 20 years. Something like
5000 or more such transplants have occurred in that time, and
there’s just a massive amount of data relating to those transplants.
One wonders whether anything new can come out of that, both in
institutional databases and international databases, and it looks as
though the answer to that question is yes.
Odim and colleagues, by asking the simple question of whether
outcomes reflect donor history has happened on something new in
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TXtransplantation. I think that the elegance of the presentation has to
do with that simple question, that simple approach to the massive
database.
There are other reports in the literature, one recently out of
Papworth in the United Kingdom, suggesting that there is no
difference in rejection rate among domino hearts versus cadaver
hearts. In researching our own database, Dr Scheule, who was
reviewing the outcomes of those babies that had hearts with less
than 90 minutes of ischemic time versus those that had more than
8 hours of ischemic time, found no difference in rejection history
either. The 8-hour case suggests some delay in procurement, which
Odim and colleagues have found to be quite a good thing.
I had organized three questions that I wanted to ask you, Dr
Odim. First of all, what do you think the minimum interval is
between brain injury and organ procurement that would result in
this favorable outcome for the recipient? I have a couple others if
you want to answer that one first.
Dr Odim. With regard to the question regarding minimal brain
injury interval, I don’t think that anybody knows. There was a
recent report out of Stanford that completely contradicts our find-
ings. In fact, they found that the shorter the duration of brain injury
and death, the better the outcome, as measured by rejection epi-
sodes. So I think there is certainly controversy. The solution to this
may require identifying specific biomarkers of brain death duration
for developing dose-responses in the pretransplant period.
Dr Bailey. The University of California Los Angeles database
is filled with adult recipients as well, presumably those older than
20 years.
Dr Odim. That’s correct.
Dr Bailey. Have you had an opportunity to look at that data-
base to see whether your findings hold true?
Dr Odim. We are in the process of actually extending these
findings to the adult database. In fact, the Stanford experience
came out of adult population, and there may be something about
the biology of mature adults.
Dr Bailey. And finally, rejection episodes included those with
and those without biopsy confirmation. Also, many but not all
recipients were managed with mycophenolate mofetil. Were these
variables included in your analysis?
Dr Odim. Yes, we included the calcineurin inhibitors, tacroli-
mus versus cyclosporine. For all intents and purposes, the immu-
nosuppression regimen beginning in about 1997 was tacrolimus
and steroids, and only in our high-risk population—those children
14 years and older or female, those with a diagnosis of congenital
heart disease, and those with mechanical assistance—was myco-
phenolate mofetil (CellCept) added to the preparation.
Dr Bailey. Well, your findings are sort of counterintuitive, and
so it’s going to behoove us to review those large databases and see
whether we can support your finding.
Dr Richard A. Jonas (Boston, Mass). Dr Bailey, what’s your
own sense, from the many, many transplants that you’ve been
involved with, regarding this issue of duration of brain injury and
transplant outcome? Even though you may not have done a formal
analysis, do you have a personal impression?
Dr Bailey. We haven’t looked at that interval. But everything
short of that would suggest that there is no real difference in
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the donors and try to support this or not.
Dr Constantine Mavroudis (Chicago, Ill). Dr Odim, I would
suggest to you to look at your data in another manner that actually
might explain some of the findings that you have presented to us
today. Namely, the ones that did poorly are the grafts from donors
with gunshot wounds to the head. You didn’t tell us anything about
blood transfusion requirements in the recipients, but I wonder
whether those had a higher blood transfusion requirement. And I
wonder if they, for some reason, imparted some other extra anti-
gens that were involved in the early rejection episodes that you
described.
There is another issue, which I think is largely in your conclu-
sion. You say that there is a longer duration of neurohormonal
discharge, without actually measuring neurohormonal discharge. I
think that this adds to the difficulty of interpreting your data. If you
were going to do this study again, then I think you ought to select
which neurohormones you want to study, study them, measure
them, and then perhaps include that in the conclusion. My personal
bias is that the data will not, in a large study, add to your
conclusion, but that remains to be seen in a randomized study.
Other than the comments that I made, my question is, did you
look at blood transfusions? Was there a significant difference in
blood transfusions in your recipients who had transplants from
gunshot wound donors?
Dr Odim. Thank you, Dr Mavroudis, for your comments. I did
not specifically look at blood transfusions. And as you well know,
not only do potential donors with gunshot wounds with many
times get transfused, so do donors with traumatic injuries, which
constituted the majority of our group and other transplantation
groups. I think that your point is well taken. Factors with regards
to transfusion, both in the donor as well as the recipient, need to be
examined.
With regard to the issue of gunshot wounds perhaps explaining
some of the data, I think your point is also well taken. Generally,
the interval of brain death is short with a destructive blast to the
brain. However, we had few deaths, and the numbers were small
enough that it was difficult to tease out a real association.
With regard to the comment regarding neurohormonal dis-
charge, I agree with you. This is speculative, and clearly the
direction that this area needs to take.
Dr Scott M. Bradley (Charleston, SC). Dr Odim, could I get
you to comment on other issues involved in donor management
and, in particular, thyroid hormone supplementation? Were those
consistent during the period of the study? Were you able to look at
any of those other issues and variables in your analysis?
Dr Odim. Essentially, at least in our sector of the world, with
our organ procurement organizations, thyroid replacement is used
probably 15% to 20% of the time. As you well know, the benefit
of the use of thyroid supplementation is quite nebulous, because
you find articles that argue in favor as well as against in terms of
the effect. Clearly, in certain instances the effect of thyroid use
does reduce the inotropic requirement of the graft before implan-
tation. Steroids are also used to combat the inflammatory response
in the donor, generally 100% of the time for the donors in our
region.
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